Project Grant R01CA279596
Award Date
5/1/23
Completion Date
4/30/28
Dollars Obligated
$537K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,905,304.00 over a five-year period from August 2024 to July 2029 to The Washington University in St. Louis to conduct research on an accelerated brachytherapy-forward chemoradiation therapy (ABC-RT) approach for the treatment of locally advanced cervical cancer. The key objectives are to: 1) Determine if the ABC-RT approach can safely shorten overall treatment time and maximize...
This federal Project Grant award, provided by the National Cancer Institute (CFDA 93.396 Cancer Biology Research program), aims to develop highly effective cancer immunotherapeutic vaccines to address global health disparities in cervical cancer associated with human papillomavirus (HPV) 16 variants. The $630,506 award, spanning 2025-2029, will fund research to: 1) characterize immune evasion by studying presentation of HPV E6/E7 epitope variants across different human MHC-1 alleles; 2) evaluate...
This $638,903 federal Cooperative Agreement award, granted by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121), aims to validate a novel prognostic biomarker for human papillomavirus-positive (HPV+) oropharyngeal cancer (OPC). The project, led by the Washington University in St. Louis, seeks to validate the "HPVHet" biomarker across over 1,000 diverse HPV+ OPC patients from the U.S., Europe, and...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program provides $184,528 to Case Western Reserve University to conduct research on the role of the vaginal microbiome and antibody-bound bacteria in human papillomavirus (HPV) infection and cervical dysplasia. The key objectives are to characterize the abundance, species/genera, and functional profiles of antibody-bound and unbound vaginal bacteria in women with and...
This Cooperative Agreement award from the National Cancer Institute (NCI), under the federal grant program "Cancer Detection and Diagnosis Research" (CFDA 93.394), aims to develop a point-of-care HPV DNA test for cervical cancer screening in Mozambique. The total award is $585,943, with a performance period from September 1, 2024 to August 31, 2029. The key objectives are to: 1) Adapt existing extraction-free, multiplexed, isothermal nucleic acid amplification assays to detect 8...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $148,280 to Childrens Hospital Medical Center in Cincinnati, Ohio to study the role of the ERBB2 protein in human papillomavirus (HPV)-induced pathologies. The research aims to spatially resolve ERBB2 expression, activation, and downstream signaling in 3D organotypic epithelial raft models of HPV-positive and HPV-negative cells. The study will also define whether ERBB2 is...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to the University of Texas Southwestern Medical Center totals $660,205 and aims to identify compounds that effectively inhibit human papillomavirus (HPV) genome replication. The key research objectives are to: Identify compounds that can block HPV replication during the establishment, maintenance, and amplification stages of the viral life cycle, focusing on compounds that...
This $643,363 Cooperative Agreement, awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), will support a hybrid type III effectiveness-implementation trial to test best practices for deploying a "screen and treat" approach to cervical cancer screening using self-collected HPV DNA testing within HIV care and treatment facilities in Mozambique. The primary outcome is to increase the number of women screened and treated for...
This federal Project Grant award, titled "GENOME-WIDE APPROACHES TO NON-INVASIVE SCREENING AND CHARACTERIZATION OF OVARIAN CANCERS", is funded by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) in the amount of $107,948. The award was made to The Johns Hopkins University, a leading research institution, and is intended to advance the understanding of ovarian tumorigenesis and develop an accessible, high-performance liquid biopsy for ovarian cancer...
This $1,284,172 Cooperative Agreement award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports a two-center, Phase II clinical trial of E7 TCR-T cell therapy for treating metastatic HPV-associated cancers. The primary goal is to assess the response rate of this novel immunotherapy approach, which leverages engineered autologous T-cells targeting the HPV E7 oncoprotein. The research will be conducted through a collaboration between Rutgers Cancer Institute of...